• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2012 Product Image

Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2012

  • ID: 2335191
  • November 2012
  • 43 pages
  • Global Markets Direct

Herpes Labialis (Oral Herpes) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes). Herpes Labialis (Oral Herpes) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Herpes Labialis (Oral Herpes).
- A review of the Herpes Labialis READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Herpes Labialis (Oral Herpes) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Herpes Labialis (Oral Herpes) 7
Herpes Labialis (Oral Herpes) Therapeutics under Development by Companies 9
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Herpes Labialis (Oral Herpes) Therapeutics – Products under Development by Companies 14
Companies Involved in Herpes Labialis (Oral Herpes) Therapeutics Development 15
BioAlliance Pharma SA 15
Nitric Biotherapeutics, Inc. 16
NanoBio Corporation 17
Redox Pharmaceutical Corporation 18
Beech Tree Labs, Inc. 19
EMS S.A. 20
Herpes Labialis (Oral Herpes) – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
acyclovir - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
doxorubicin - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
NB-001 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
BTL-TML-HSV - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
acyclovir - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
penciclovir - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Herpes Labialis (Oral Herpes) Therapeutics – Drug Profile Updates 33
Herpes Labialis (Oral Herpes) Therapeutics - Dormant Products 36
Herpes Labialis (Oral Herpes) – Product Development Milestones 37
Featured News & Press Releases 37
Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig 37
May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier 37
Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure 38
May 11, 2011: NanoBio And GSK Commence Phase III Studies Of Nanoemulsion-based OTC Treatment For Cold Sores 38
Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis 39
Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting 39
Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress 40
Sep 14, 2010: Beech Tree Labs Initiates Phase I/IIa Oral Herpes Trial 40
Sep 07, 2010: BioAlliance Pharma Receives European Patent For Acyclovir Lauriad 40
Aug 26, 2010: BioAlliance Pharma Plans To Submit Acyclovir Lauriad NDA 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Number of Products Under Development for Herpes Labialis (Oral Herpes), H2 2012 7
Products under Development for Herpes Labialis (Oral Herpes) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
BioAlliance Pharma SA, H2 2012 15
Nitric Biotherapeutics, Inc., H2 2012 16
NanoBio Corporation, H2 2012 17
Redox Pharmaceutical Corporation, H2 2012 18
Beech Tree Labs, Inc., H2 2012 19
EMS S.A., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Herpes Labialis (Oral Herpes) Therapeutics – Drug Profile Updates 33
Herpes Labialis (Oral Herpes) Therapeutics – Dormant Products 36

List of Figures
Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2012 7
Products under Development for Herpes Labialis (Oral Herpes) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos